Synlogic, Inc. (SYBX)

Market Cap	7.19M -56.1%
Revenue (ttm)	n/a -99.8%
Net Income	-3.23M
EPS	-0.26
Shares Out	11.68M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	134
Average Volume	10,942
Open	0.6000
Previous Close	0.6150
Day's Range	0.6000 - 0.6000
52-Week Range	0.5401 - 1.9600
Beta	0.53
RSI	35.60
Earnings Date	Mar 16, 2026

About Synlogic

Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The com...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Mary Dooley
• Employees: 1
• Stock Exchange: OTCMKTS
• Ticker Symbol: SYBX

Financial Performance

In 2024, Synlogic's revenue was $8,000, a decrease of -99.76% compared to the previous year's $3.37 million. Losses were -$23.36 million, -61.88% less than in 2023.